Skip to content
中文产业新闻评分66Chinese source

T-DXd+P正式获NMPA批准，用于HER2阳性晚期乳腺癌一线治疗

再下一城！T-DXd+P正式获NMPA批准，我国HER2阳性晚期乳腺癌一线治疗迎来新选择

Original articleChinese edition

No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.